Table 1

Baseline characteristics in the full cohort

Rituximab first lineRituximab later lineOther DMT first lineOther DMT later lineGeneral population
Number of observations145832362774327520 308
Start year, median (IQR)2018 (2016–2019)2017 (2015–2018)2015 (2014–2018)2014 (2013–2016)2017 (2016–2019)
Age in years, mean (SD)38.0 (11.3)40.4 (10.4)36.2 (10.6)39.3 (10.3)39.6 (10.7)
Female, n (%)937 (64.3)2282 (70.5)1904 (68.6)2341 (71.5)13 683 (67.4)
Born in Sweden, n (%)1231 (84.5)2769 (85.6)2328 (84.0)2847 (87.0)16 373 (80.6)
Education, 12+ years, n (%)669 (46.6)1490 (46.4)1227 (45.0)1553 (47.8)9342 (46.7)
Years since MS diagnosis, mean (SD)1.0 (3.4)7.6 (6.0)1.0 (3.4)6.5 (5.6)
Hospitalised infection 5 years before DMT, n (%)36 (2.5)126 (3.9)79 (2.8)107 (3.3)501 (2.5)
Infection outpatient care 5 years before DMT, n (%)208 (14.3)475 (14.7)355 (12.8)445 (13.6)2224 (11.0)
Antibiotics 5 years before DMT, n (%)737 (50.5)1893 (58.5)1461 (52.7)1945 (59.4)9832 (48.4)
Charlson Comorbidity Index, mean (SD)0.2 (0.6)0.1 (0.6)0.2 (0.6)0.1 (0.5)0.1 (0.5)
Any relapse year before DMT, n (%)517 (35.5)648 (20.0)1114 (40.2)860 (26.3)
EDSS, mean (SD)1.7 (1.3)1.8 (1.4)1.5 (1.3)1.7 (1.4)
MSIS-29 physical, mean (SD)1.8 (0.8)1.8 (0.8)1.8 (0.8)1.8 (0.8)
MSIS-29 psychological, mean (SD)2.4 (1.0)2.2 (0.9)2.4 (1.0)2.2 (0.9)
Duration of previous DMT, years, mean (SD)3.4 (3.4)3.4 (3.6)
History of natalizumab, n (%)0 (0.0)1196 (37.0)0 (0.0)480 (14.7)
History of fingolimod, n (%)0 (0.0)560 (17.3)0 (0.0)238 (7.3)
History of dimethyl fumarate, n (%)0 (0.0)847 (26.2)0 (0.0)354 (10.8)
No previous DMT, n (%)1458 (100.0)2774 (100.0)
1 previous DMT, n (%)1560 (48.2)2188 (66.8)
2 previous DMTs, n (%)1083 (33.5)836 (25.5)
3+ previous DMTs, n (%)593 (18.3)251 (7.7)
Reason for previous treatment stop, n (%)
 Adverse events719 (22.3)974 (29.8)
 Loss of effect1117 (34.6)1329 (40.7)
 Other1390 (43.1)963 (29.5)
  • DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; MSIS-29, Multiple Sclerosis Impact Scale.